Study for congenital glycosylation disorders and NGLY1 deficiency
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial is for people who have a confirmed genetic condition related to how the body builds certain sugar-like structures (CDG) or NGLY1 deficiency. It aims to better understand these conditions through clinical and basic science research, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CDG (congenital disorders of glycosylation)
- Your CDG diagnosis must be confirmed by genetic, enzyme, or molecular testing
- OR you must have a confirmed diagnosis of NGLY1 deficiency
- Your diagnosis must be supported by genetic, enzyme, or molecular testing
- There are no listed exclusion criteria for this trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors diagnose congenital (from birth) glycosylation disorders, which are inherited conditions that affect how the body builds certain sugar-related proteins. You (or your child) may have clinic visits, blood or other samples, and possibly genetic testing—especially if there are family members with a known or suspected condition.
This study is creating a registry (a database) to better understand glycogen storage diseases in Indian children. If your child has a confirmed genetic diagnosis, joining helps doctors learn more about the condition and improve care.
This study tests a sugar called D-galactose to see if it is safe and works well for people with PGM1-CDG, a rare genetic condition that affects how the body uses sugar. If you are already taking D-galactose, this trial will check if it helps your symptoms.
This study follows people with certain inherited metabolic conditions (like GM1 or GM2 gangliosidosis, sialidosis, or galactosialidosis) to learn more about how these diseases progress over time. Participating may help researchers understand the conditions better, which could improve future care.
This study looks at children who may have genetic (inherited) or metabolic (body chemistry) problems, including newborn screening and episodes of trouble. The goal is to better understand these conditions and identify children who may benefit from further care.
This trial tests a new oral medicine, nizubaglustat (AZ-3102), for children and adults (4+) with late-infantile or juvenile Niemann-Pick type C, GM1, or GM2 gangliosidosis. It aims to see if the drug is safe and helps slow disease progression.
Hear when a new Congenital Disorders of Glycosylation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.